Investors must take note of Spyre Therapeutics Inc’s (SYRE) performance last week, which was 1.40%.

On Monday, Spyre Therapeutics Inc (NASDAQ: SYRE) was -4.99% drop from the session before settling in for the closing price of $16.02. A 52-week range for SYRE has been $10.91 – $40.26.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 44.65% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 2.86%. With a float of $51.32 million, this company’s outstanding shares have now reached $60.28 million.

In an organization with 65 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Spyre Therapeutics Inc (SYRE) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Spyre Therapeutics Inc stocks. The insider ownership of Spyre Therapeutics Inc is 14.97%, while institutional ownership is 99.28%. The most recent insider transaction that took place on Nov 06 ’24, was worth 246,313. In this transaction Director of this company sold 6,700 shares at a rate of $36.76, taking the stock ownership to the 27,360 shares. Before that another transaction happened on Oct 25 ’24, when Company’s Director sold 300 for $36.43, making the entire transaction worth $10,929. This insider now owns 34,060 shares in total.

Spyre Therapeutics Inc (SYRE) Latest Financial update

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.77 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 2.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.28% during the next five years compared to 44.65% growth over the previous five years of trading.

Spyre Therapeutics Inc (NASDAQ: SYRE) Trading Performance Indicators

You can see what Spyre Therapeutics Inc (SYRE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.06.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -3.30 in one year’s time.

Technical Analysis of Spyre Therapeutics Inc (SYRE)

Let’s dig in a bit further. During the last 5-days, its volume was 0.84 million. That was better than the volume of 0.64 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 42.17%.

During the past 100 days, Spyre Therapeutics Inc’s (SYRE) raw stochastic average was set at 30.96%, which indicates a significant increase from 24.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.91% in the past 14 days, which was lower than the 74.62% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $15.15, while its 200-day Moving Average is $22.31. However, in the short run, Spyre Therapeutics Inc’s stock first resistance to watch stands at $15.87. Second resistance stands at $16.52. The third major resistance level sits at $16.92. If the price goes on to break the first support level at $14.82, it is likely to go to the next support level at $14.43. The third support level lies at $13.78 if the price breaches the second support level.

Spyre Therapeutics Inc (NASDAQ: SYRE) Key Stats

There are 60,276K outstanding shares of the company, which has a market capitalization of 918.58 million. As of now, sales total 0 K while income totals -208,020 K. Its latest quarter income was 0 K while its last quarter net income were -44,770 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.